202 related articles for article (PubMed ID: 29700392)
1. EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.
Toosi BM; El Zawily A; Truitt L; Shannon M; Allonby O; Babu M; DeCoteau J; Mousseau D; Ali M; Freywald T; Gall A; Vizeacoumar FS; Kirzinger MW; Geyer CR; Anderson DH; Kim T; Welm AL; Siegel P; Vizeacoumar FJ; Kusalik A; Freywald A
Oncogene; 2018 Jul; 37(30):4073-4093. PubMed ID: 29700392
[TBL] [Abstract][Full Text] [Related]
2. The intrinsically kinase-inactive EPHB6 receptor predisposes cancer cells to DR5-induced apoptosis by promoting mitochondrial fragmentation.
El Zawily AM; Toosi BM; Freywald T; Indukuri VV; Vizeacoumar FJ; Leary SC; Freywald A
Oncotarget; 2016 Nov; 7(47):77865-77877. PubMed ID: 27788485
[TBL] [Abstract][Full Text] [Related]
3. Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.
Paul JM; Toosi B; Vizeacoumar FS; Bhanumathy KK; Li Y; Gerger C; El Zawily A; Freywald T; Anderson DH; Mousseau D; Kanthan R; Zhang Z; Vizeacoumar FJ; Freywald A
Oncotarget; 2016 Aug; 7(31):50027-50042. PubMed ID: 27418135
[TBL] [Abstract][Full Text] [Related]
4. Modulation of liver-intestine cadherin (Cadherin 17) expression, ERK phosphorylation and WNT signaling in EPHB6 receptor-expressing MDA-MB-231 cells.
Bhushan L; Tavitian N; Dey D; Tumur Z; Parsa C; Kandpal RP
Cancer Genomics Proteomics; 2014; 11(5):239-49. PubMed ID: 25331796
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy.
He J; Lee HJ; Saha S; Ruan D; Guo H; Chan CH
Cell Death Dis; 2019 Mar; 10(4):285. PubMed ID: 30918246
[TBL] [Abstract][Full Text] [Related]
6. Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer.
Stratford AL; Reipas K; Maxwell C; Dunn SE
Expert Rev Mol Med; 2010 Jul; 12():e22. PubMed ID: 20653987
[TBL] [Abstract][Full Text] [Related]
7. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
8. The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells.
Truitt L; Freywald T; DeCoteau J; Sharfe N; Freywald A
Cancer Res; 2010 Feb; 70(3):1141-53. PubMed ID: 20086179
[TBL] [Abstract][Full Text] [Related]
9. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options.
Burnett JP; Korkaya H; Ouzounova MD; Jiang H; Conley SJ; Newman BW; Sun L; Connarn JN; Chen CS; Zhang N; Wicha MS; Sun D
Sci Rep; 2015 Nov; 5():15821. PubMed ID: 26522776
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation maintains the CLDN1-EPHB6-SLUG axis to enhance chemotherapeutic efficacy and inhibit lung cancer progression.
Wu JE; Wu YY; Tung CH; Tsai YT; Chen HY; Chen YL; Hong TM
Theranostics; 2020; 10(19):8903-8923. PubMed ID: 32754286
[TBL] [Abstract][Full Text] [Related]
12. Ligand stimulation induces clathrin- and Rab5-dependent downregulation of the kinase-dead EphB6 receptor preceded by the disruption of EphB6-Hsp90 interaction.
Allonby O; El Zawily AM; Freywald T; Mousseau DD; Chlan J; Anderson D; Benmerah A; Sidhu V; Babu M; DeCoteau J; Freywald A
Cell Signal; 2014 Dec; 26(12):2645-57. PubMed ID: 25152371
[TBL] [Abstract][Full Text] [Related]
13. DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-Positive Breast Cancer Following Endocrine Therapy.
Peiffer DS; Wyatt D; Zlobin A; Piracha A; Ng J; Dingwall AK; Albain KS; Osipo C
Cancer Res; 2019 Oct; 79(19):4965-4977. PubMed ID: 31387918
[TBL] [Abstract][Full Text] [Related]
14. A paradigm shift in EPH receptor interaction: biological relevance of EPHB6 interaction with EPHA2 and EPHB2 in breast carcinoma cell lines.
Fox BP; Kandpal RP
Cancer Genomics Proteomics; 2011; 8(4):185-93. PubMed ID: 21737611
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
16. NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling.
Zhang J; Shao X; Sun H; Liu K; Ding Z; Chen J; Fang L; Su W; Hong Y; Li H; Li H
Oncotarget; 2016 Sep; 7(38):61036-61053. PubMed ID: 27506933
[TBL] [Abstract][Full Text] [Related]
17. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
[TBL] [Abstract][Full Text] [Related]
19. Targeting CSC in a Most Aggressive Subtype of Breast Cancer TNBC.
Bao B; Prasad AS
Adv Exp Med Biol; 2019; 1152():311-334. PubMed ID: 31456192
[TBL] [Abstract][Full Text] [Related]
20. Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions.
Damelin M; Bankovich A; Park A; Aguilar J; Anderson W; Santaguida M; Aujay M; Fong S; Khandke K; Pulito V; Ernstoff E; Escarpe P; Bernstein J; Pysz M; Zhong W; Upeslacis E; Lucas J; Lucas J; Nichols T; Loving K; Foord O; Hampl J; Stull R; Barletta F; Falahatpisheh H; Sapra P; Gerber HP; Dylla SJ
Clin Cancer Res; 2015 Sep; 21(18):4165-73. PubMed ID: 26015513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
